Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Thomas R FritscheRonald N Jones

Abstract

NVP PDF-713 (LBM 415) is a peptide deformylase inhibitor being progressed into clinical trials. Dry-form broth microdilution panels of NVP PDF-713 were compared to reference MIC panels of 552 recent clinical isolates. Most (99.2%) dry-form MIC results were within +/- 1 log(2) dilution of the reference panel MICs. Of the bacteria tested, Streptococcus pneumoniae and Haemophilus influenzae showed a bias towards higher and lower MICs, respectively. Same-day and between-day reproducibility tests showed that 98.9% and 96.7% of MIC values, respectively, were within +/- 1 log(2) dilution step, thereby demonstrating a high degree of reliability of the dry-form MIC product for clinical studies.

References

Feb 13, 2001·Antimicrobial Agents and Chemotherapy·J M ClementsM G Hunter
Mar 21, 2001·Antimicrobial Agents and Chemotherapy·C M ApfelW Keck
Jun 22, 2001·The Journal of Antimicrobial Chemotherapy·A L BarryS D Brown
Mar 19, 2002·Antimicrobial Agents and Chemotherapy·R WiseJ Ashby
Dec 21, 2002·The Journal of Antimicrobial Chemotherapy·Ronald N Jones, Paul R Rhomberg
May 22, 2003·Journal of the American Geriatrics Society·UNKNOWN AGS Clinical Practice Committee
Jul 3, 2003·The Journal of Antimicrobial Chemotherapy·Gunnar KahlmeterAlkiviadis Vatopoulos
Jul 5, 2003·International Journal of Antimicrobial Agents·Tamara R AndereggUNKNOWN Quality Control Working Group

❮ Previous
Next ❯

Citations

May 10, 2005·Diagnostic Microbiology and Infectious Disease·Paul R Rhomberg, Ronald N Jones
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Tatiana BogdanovichPeter C Appelbaum
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Lois M EdniePeter C Appelbaum
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Kim CreditoPeter C Appelbaum
Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Thomas R FritscheRonald N Jones
Sep 8, 2005·Expert Opinion on Investigational Drugs·D Chen, Z Yuan
Jul 1, 2011·Clinical Pharmacology and Therapeutics·P RolanT G Evans

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
R N JonesDouglas J Biedenbach
Diagnostic Microbiology and Infectious Disease
Tamara R AndereggQuality Control Working Group
International Journal of Antimicrobial Agents
Tamara R AndereggQuality Control Working Group
© 2021 Meta ULC. All rights reserved